Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 7/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 7/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341691 | 0.94 | KMO (0.46) | KMOLDHADHODHSCN9A | |
| SCHEMBL3341300 | 0.90 | KMO (0.40) | KMOSCN9ASCN5A | |
| SCHEMBL3345443 | 0.89 | KMO (0.44) | KMOLDHADHODHSCN9ASCN5A | |
| SCHEMBL3342587 | 0.88 | KMO (0.47) | KMOLDHASCN9A | |
| SCHEMBL3345267 | 0.86 | KMO (0.45) | KMODHODHSCN5A | |
| SCHEMBL3341278 | 0.84 | SCN9A (0.43) | KMOSCN9ASCN5A | |
| SCHEMBL3339524 | 0.83 | KMO (0.44) | KMOLDHADHODHSCN9ASCN5A | |
| SCHEMBL3341930 | 0.80 | SCN8A (0.41) | KMODHODHSCN9ASCN5A | |
| SCHEMBL3341309 | 0.78 | CHRNA7 (0.42) | KMOLDHASCN9ASCN5A | |
| SCHEMBL3340026 | 0.78 | LDHA (0.51) | LDHADHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-06-24 | — | — | US | disclosed |
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-06-24 | — | — | US | disclosed |
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-06-24 | — | — | US | disclosed |
| WO-2008031500-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | PPARA, PPARD, PPARG | KMO 1885/4885LDHA 3407/4885DHODH 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.